ES3027194T3 - Mutant bordetella strains and methods for use - Google Patents

Mutant bordetella strains and methods for use Download PDF

Info

Publication number
ES3027194T3
ES3027194T3 ES17715426T ES17715426T ES3027194T3 ES 3027194 T3 ES3027194 T3 ES 3027194T3 ES 17715426 T ES17715426 T ES 17715426T ES 17715426 T ES17715426 T ES 17715426T ES 3027194 T3 ES3027194 T3 ES 3027194T3
Authority
ES
Spain
Prior art keywords
pertactin
subject
deficient
composition
strain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES17715426T
Other languages
English (en)
Spanish (es)
Inventor
Luis Solans
Camille Locht
Anne Tsicopoulos
Yahia Sendid Saliha Ait
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut Pasteur de Lille
Institut National de la Sante et de la Recherche Medicale INSERM
Institut Pasteur
Original Assignee
Institut Pasteur de Lille
Institut National de la Sante et de la Recherche Medicale INSERM
Institut Pasteur
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut Pasteur de Lille, Institut National de la Sante et de la Recherche Medicale INSERM, Institut Pasteur filed Critical Institut Pasteur de Lille
Application granted granted Critical
Publication of ES3027194T3 publication Critical patent/ES3027194T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/42—Respiratory system, e.g. lungs, bronchi or lung cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/099—Bordetella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/235—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Bordetella (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/36—Adaptation or attenuation of cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K2039/10—Brucella; Bordetella, e.g. Bordetella pertussis; Not used, see subgroups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Wood Science & Technology (AREA)
  • Rheumatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Physiology (AREA)
  • Developmental Biology & Embryology (AREA)
ES17715426T 2016-03-29 2017-03-29 Mutant bordetella strains and methods for use Active ES3027194T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662314843P 2016-03-29 2016-03-29
PCT/EP2017/057468 WO2017167834A1 (en) 2016-03-29 2017-03-29 Mutant bordetella strains and methods for use

Publications (1)

Publication Number Publication Date
ES3027194T3 true ES3027194T3 (en) 2025-06-13

Family

ID=58488973

Family Applications (1)

Application Number Title Priority Date Filing Date
ES17715426T Active ES3027194T3 (en) 2016-03-29 2017-03-29 Mutant bordetella strains and methods for use

Country Status (11)

Country Link
US (4) US10682377B2 (enExample)
EP (2) EP4541809A3 (enExample)
JP (1) JP6993984B2 (enExample)
CN (2) CN114767718A (enExample)
AU (2) AU2017242541B2 (enExample)
CA (1) CA3018126A1 (enExample)
DK (1) DK3436034T3 (enExample)
ES (1) ES3027194T3 (enExample)
FI (1) FI3436034T3 (enExample)
SG (1) SG11201807783UA (enExample)
WO (1) WO2017167834A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0707102B1 (pt) * 2006-03-10 2022-05-31 Institut Pasteur De Lille Composição imunogênica
CA2759280C (en) 2009-04-28 2016-09-20 Inserm (Institut National De La Sante Et De La Recherche Medicale) Vaccine for prophylaxis or treatment of an allergen-driven airway pathology
AU2017242541B2 (en) * 2016-03-29 2022-06-30 Institut National De La Sante Et De La Recherche Medicale (Inserm) Mutant bordetella strains and methods for use
CA3077428A1 (en) 2017-10-18 2019-04-25 Institut Pasteur De Lille Bordetella strains expressing serotype 3 fimbriae
BR112023002549A2 (pt) 2020-08-14 2023-03-07 Iliad Biotechnologies Llc Método de fabricação de uma vacina liofilizada compreendendo bactérias bordetella vivas atenuadas e produto de vacina liofilizada
CN116635517A (zh) 2020-11-17 2023-08-22 伊利亚德生物技术有限公司 与神经退行性疾病相关的神经病理的治疗和预防
JP2025525623A (ja) 2022-07-22 2025-08-05 アンスティチュ ナシヨナル デュ ラ サンテ エト デュ ラ レシェルシェ メディカレ 慢性閉塞性肺疾患の治療のためのボルデテラ（ｂｏｒｄｅｔｅｌｌａ）菌株の使用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6713072B1 (en) 1987-11-02 2004-03-30 Chiron S.R.L. Immunologically active polypeptides with altered toxicity useful for the preparation of an antipertussis vaccine
GB9115332D0 (en) * 1991-07-16 1991-08-28 Connaught Lab Manipulation of gene copy number in bordetella
FR2718750B1 (fr) 1994-04-19 1996-06-14 Pasteur Institut Protéines recombinantes de l'hémagglutinine filamenteuse de Bordetella, notamment, B. Pertussis, production et application à la production de protéines étrangères ou de principes actifs vaccinants.
CN1147259A (zh) * 1994-04-28 1997-04-09 武田药品工业株式会社 分离百日咳杆菌保护性组分的方法
FR2754543B1 (fr) * 1996-10-11 1998-12-31 Pasteur Institut Souche de bordetella deficiente dans la production de toxine et exprimant une proteine hydride, liposomes comprenant de la fha et leurs utilisations comme vaccins, et utilisation de la fha pour stimuler les reponses immunitaires
FR2840319B1 (fr) 2002-05-30 2004-08-20 Pasteur Institut Souches de bordetella rendues deficientes par attenuation genetique
EP1617805A4 (en) 2003-04-11 2012-07-04 Medimmune Llc METHODS FOR PREVENTING OR TREATING RESPIRATORY CONDITIONS
BRPI0707102B1 (pt) 2006-03-10 2022-05-31 Institut Pasteur De Lille Composição imunogênica
WO2008058396A1 (en) 2006-11-15 2008-05-22 Folia Biotech Inc. Papaya mosaic virus-based vaccines for influenza
EP2134359A4 (en) 2007-02-23 2010-06-16 Penn State Res Found USE OF A NONVIRULENT BORDETELLA MUTANT AS LIVING VACCINE VECTOR
US20100104533A1 (en) 2007-06-18 2010-04-29 Carter William A Early intervention of viral infection with immune activators
CA2759280C (en) * 2009-04-28 2016-09-20 Inserm (Institut National De La Sante Et De La Recherche Medicale) Vaccine for prophylaxis or treatment of an allergen-driven airway pathology
JP5551774B2 (ja) 2009-06-15 2014-07-16 ナショナル ユニヴァーシティー オブ シンガポール インフルエンザワクチン、組成物、および使用方法
US9415077B2 (en) * 2011-11-02 2016-08-16 Institut National De La Sante Et De La Recherche Medicale Effect of an attenuated Bordetella strain against allergic disease
CN102793915B (zh) * 2012-07-25 2013-10-23 天津康希诺生物技术有限公司 一种无细胞百日咳疫苗的生产方法
EP2722338A1 (en) 2012-10-17 2014-04-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Novel recombinant Bordetella strains
AU2017242541B2 (en) * 2016-03-29 2022-06-30 Institut National De La Sante Et De La Recherche Medicale (Inserm) Mutant bordetella strains and methods for use

Also Published As

Publication number Publication date
EP4541809A3 (en) 2025-06-25
FI3436034T3 (fi) 2025-05-08
US11065276B2 (en) 2021-07-20
CN114767718A (zh) 2022-07-22
EP3436034B1 (en) 2025-03-26
AU2022221438B2 (en) 2024-10-03
JP2019513722A (ja) 2019-05-30
EP3436034A1 (en) 2019-02-06
US20170283890A1 (en) 2017-10-05
DK3436034T3 (da) 2025-05-12
CN109069535B (zh) 2022-03-18
AU2017242541B2 (en) 2022-06-30
US10682377B2 (en) 2020-06-16
JP6993984B2 (ja) 2022-02-03
CN109069535A (zh) 2018-12-21
AU2017242541A1 (en) 2018-10-11
AU2022221438A1 (en) 2022-10-06
EP4541809A2 (en) 2025-04-23
US20200323901A1 (en) 2020-10-15
SG11201807783UA (en) 2018-10-30
US20210290667A1 (en) 2021-09-23
WO2017167834A1 (en) 2017-10-05
CA3018126A1 (en) 2017-10-05
US20230381224A1 (en) 2023-11-30

Similar Documents

Publication Publication Date Title
ES3027194T3 (en) Mutant bordetella strains and methods for use
Solans et al. IL-17-dependent SIgA-mediated protection against nasal Bordetella pertussis infection by live attenuated BPZE1 vaccine
Solans et al. The role of mucosal immunity in pertussis
US12403188B2 (en) Bordetella strains expressing serotype 3 fimbriae
JP2004536106A (ja) マイコプラズマ・ボビスワクチンおよび動物の肺炎を減少させる方法
KR101818901B1 (ko) 돼지흉막폐렴균의 재조합 ApxIA, ApxIIA, ApxIIIA toxin의 N 또는 C 말단 분자 및 불활화 돼지흉막폐렴균을 이용한 돼지 흉막폐렴 백신 조성물
JP2019513722A5 (enExample)
JP2005112865A (ja) 百日咳菌ワクチン用アジュバントとしてのｉｌ−１２
WO2020049133A1 (en) Adenylate cyclase catalytic domain deficient bordetella strains
Mielcarek et al. Attenuated Bordetella pertussis: new live vaccines for intranasal immunisation
He et al. Vaccination with a Brucella ghost developed through a double inactivation strategy provides protection in Guinea pigs and cattle
Mann et al. Use of a genetically defined double mutant strain of Bordetella bronchiseptica lacking adenylate cyclase and type III secretion as a live vaccine
Hur et al. Immunologic study and optimization of Salmonella delivery strains expressing adhesin and toxin antigens for protection against progressive atrophic rhinitis in a murine model
HK1262896B (zh) 突变型博德特氏菌属菌株及其使用方法
HK1262896A1 (en) Mutant bordetella strains and methods for use
HK40026630B (zh) 表达血清3型菌毛的鲍特菌属菌株
Pilione et al. Use of a Genetically Defined Double Mutant